华海药业：获得卡格列净片药品注册证书

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Canagliflozin tablets, which are primarily used to improve blood sugar control in adults with type 2 diabetes [1] Summary by Relevant Sections Product Development - Canagliflozin tablets are expected to generate approximately 370 million yuan in sales in the domestic market by 2024, according to data from Meini Network [1] - The company has invested around 5.64 million yuan in the research and development of this drug [1] Market Impact - The approval of the registration certificate will enrich the company's product line and enhance its market competitiveness [1] - The introduction of Canagliflozin tablets is anticipated to have a positive impact on the company's operating performance [1]